Using this definition, an improved pCR rate due to neoadjuvant bevacizumab therapy was observed only in the “triple-negative breast cancer (TNBC)” subgroup (i.e., HER2− as well as negative for the estrogen receptor (ER) and progesterone receptor (PgR))10. Here, ESR1 is linked to triple-negative breast carcinoma.